{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:25:54Z","timestamp":1784589954721,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,15]]},"DOI":"10.7759\/cureus.28043","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:46:34Z","timestamp":1660610794000},"source":"Crossref","is-referenced-by-count":1,"title":["Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis"],"prefix":"10.7759","author":[{"given":"Amber Loren O","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima N","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Jairam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel X","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry S","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn D","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3367","article-title":"Early-stage mycosis fungoides: epidemiology and prognosis","volume":"100","author":"Maguire A","year":"2020","unstructured":"Maguire A, Puelles J, Raboisson P, Chavda R, Gabriel S, Thornton S. Early-stage mycosis fungoides: epidemiology and prognosis. Acta Derm Venereol. 2020, 100:adv00013. 10.2340\/00015555-3367","journal-title":"Acta Derm Venereol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2629","article-title":"Morbidity and causes of death in patients with cutaneous T-cell lymphoma in Finland","volume":"97","author":"V\u00e4kev\u00e4 L","year":"2017","unstructured":"V\u00e4kev\u00e4 L, Lipsanen T, Sintonen H, Ranki A. Morbidity and causes of death in patients with cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2017, 97:735-738. 10.2340\/00015555-2629","journal-title":"Acta Derm Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-2217","article-title":"Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity","volume":"123","author":"Huang JT","year":"2009","unstructured":"Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009, 123:e808-e814. 10.1542\/peds.2008-2217","journal-title":"Pediatrics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1779259","article-title":"Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL)","volume":"61","author":"Allen PB","year":"2020","unstructured":"Allen PB, Switchenko J, Ayers A, Kim E, Lechowicz MJ. Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL). Leuk Lymphoma. 2020, 61:2652-2658. 10.1080\/10428194.2020.1779259","journal-title":"Leuk Lymphoma"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim EJ","year":"2005","unstructured":"Kim EJ, Hess S, Richardson SK, et al.. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005, 115:798-812. 10.1172\/JCI24826","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.11.692","article-title":"Infectious agents in cutaneous T-cell lymphoma","volume":"64","author":"Mirvish ED","year":"2011","unstructured":"Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2011, 64:423-431. 10.1016\/j.jaad.2009.11.692","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"28","author":"Quaglino P","year":"2017","unstructured":"Quaglino P, Maule M, Prince HM, et al.. Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol. 2017, 28:2517-2525. 10.1093\/annonc\/mdx352","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic M","year":"2001","unstructured":"Duvic M, Hymes K, Heald P, et al.. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001, 19:2456-2471. 10.1200\/JCO.2001.19.9.2456","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21836","article-title":"Development of iron deficiency anemia in patients undergoing extracorporeal photopheresis: comparison of the UVAR and CELLEX instruments","volume":"36","author":"Moosavi MM","year":"2021","unstructured":"Moosavi MM, Goodman AL, Duncan A, Stowell SR, Waller EK, Roback JD, Sullivan HC. Development of iron deficiency anemia in patients undergoing extracorporeal photopheresis: comparison of the UVAR and CELLEX instruments. J Clin Apher. 2021, 36:34-40. 10.1002\/jca.21836","journal-title":"J Clin Apher"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmy034","article-title":"Iron deficiency anemia in patients undergoing extracorporeal photopheresis for cutaneous T-cell lymphoma","volume":"50","author":"Sanford KW","year":"2019","unstructured":"Sanford KW, Anderson J, Roseff S, McPherson RA. Iron deficiency anemia in patients undergoing extracorporeal photopheresis for cutaneous T-cell lymphoma. Lab Med. 2019, 50:29-33. 10.1093\/labmed\/lmy034","journal-title":"Lab Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120163","article-title":"Romidepsin for the treatment of T-cell lymphomas","volume":"70","author":"McGraw AL","year":"2013","unstructured":"McGraw AL. Romidepsin for the treatment of T-cell lymphomas. Am J Health Syst Pharm. 2013, 70:1115-1122. 10.2146\/ajhp120163","journal-title":"Am J Health Syst Pharm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/11207170-000000000-00000","article-title":"Romidepsin: in the treatment of T-cell lymphoma","volume":"71","author":"Yang LP","year":"2011","unstructured":"Yang LP. Romidepsin: in the treatment of T-cell lymphoma. Drugs. 2011, 71:1469-1480. 10.2165\/11207170-000000000-00000","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23112","article-title":"The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients","volume":"87","author":"Kelly-Sell MJ","year":"2012","unstructured":"Kelly-Sell MJ, Kim YH, Straus S, et al.. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol. 2012, 87:354-360. 10.1002\/ajh.23112","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim YH","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003, 139:857-866. 10.1001\/archderm.139.7.857","journal-title":"Arch Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.03771.x","article-title":"Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma","volume":"48","author":"Vidulich KA","year":"2009","unstructured":"Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol. 2009, 48:243-252. 10.1111\/j.1365-4632.2009.03771.x","journal-title":"Int J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1466026","article-title":"Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis","volume":"29","author":"Tsang Y","year":"2018","unstructured":"Tsang Y, Gu T, Sharma G, Raspa S, Drake B 3rd, Tan H. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. J Dermatolog Treat. 2018, 29:747-753. 10.1080\/09546634.2018.1466026","journal-title":"J Dermatolog Treat"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1520987","article-title":"Association of insurance status with survival in patients with cutaneous T-cell lymphoma","volume":"60","author":"Tang R","year":"2019","unstructured":"Tang R, Su C, Bai HX, et al.. Association of insurance status with survival in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2019, 60:1253-1260. 10.1080\/10428194.2018.1520987","journal-title":"Leuk Lymphoma"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar K","year":"2013","unstructured":"Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013, 149:1295-1299. 10.1001\/jamadermatol.2013.5526","journal-title":"JAMA Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-012-0038-2","article-title":"Update on epidemiology of cutaneous T-cell lymphoma","volume":"2","author":"Samimi S","year":"2013","unstructured":"Samimi S, Rook AH, Kim EJ. Update on epidemiology of cutaneous T-cell lymphoma. Curr Dermatol Rep. 2013, 2:35-41. 10.1007\/s13671-012-0038-2","journal-title":"Curr Dermatol Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*","volume":"132","author":"Thursky KA","year":"2006","unstructured":"Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol. 2006, 132:3-12. 10.1111\/j.1365-2141.2005.05789.x","journal-title":"Br J Haematol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen EA","year":"2016","unstructured":"Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, Lim HW. Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016, 74:27-58. 10.1016\/j.jaad.2015.09.033","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419840629","article-title":"Existing and emerging therapies for cutaneous T-cell lymphoma","volume":"23","author":"Van-de-Velde V","year":"2019","unstructured":"Van-de-Velde V, Zhou Y. Existing and emerging therapies for cutaneous T-cell lymphoma. J Cutan Med Surg. 2019, 23:319-327. 10.1177\/1203475419840629","journal-title":"J Cutan Med Surg"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook AH","year":"2015","unstructured":"Rook AH, Gelfand JM, Wysocka M, et al.. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015, 126:1452-1461. 10.1182\/blood-2015-02-630335","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.720372","article-title":"Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma","volume":"54","author":"Duvic M","year":"2013","unstructured":"Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma. 2013, 54:514-519. 10.3109\/10428194.2012.720372","journal-title":"Leuk Lymphoma"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.94","article-title":"Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas","volume":"6","author":"Remer M","year":"2014","unstructured":"Remer M, Al-Shamkhani A, Glennie M, Johnson P. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immunotherapy. 2014, 6:1187-1206. 10.2217\/imt.14.94","journal-title":"Immunotherapy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/106269-factors-associated-with-in-hospital-mortality-in-mycosis-fungoides-patients-a-multivariable-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:14Z","timestamp":1707507554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/106269-factors-associated-with-in-hospital-mortality-in-mycosis-fungoides-patients-a-multivariable-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.28043","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,15]]}}}